Original Sky Meter Intranet
Highlights
A few days ago, the West China Second Hospital of Sichuan University announced that it plans to publicly introduce 172 drugs to meet the needs of clinical drugs, including chemical drugs, biological products and Chinese patent medicines, of which exclusive varieties (including dosage forms exclusive, the same below) account for more than 30%;
Source: Official website of West China Second Hospital, Sichuan University
According to the statistics of treatment categories, the drugs to be introduced by the West China Second Hospital of Sichuan University are mainly nervous system drugs and dermatology drugs, accounting for 21 and 20 seats respectively, while digestive system and metabolic drugs, anti-tumor and immunomodulators, systemic anti-infective drugs, blood and hematopoietic system drugs and respiratory system drugs account for 16, 15, 15, 14 and 10 respectively.
Among the 172 drugs to be introduced, there are 62 exclusive varieties, accounting for more than 30%, of which 39 are chemical drugs, 13 are Chinese patent medicines, and 10 are biological products. From the enterprise level, the number of products that Zhengda Tianqing Pharmaceutical, Beite Pharmaceutical, Hengrui Pharmaceutical and other enterprises plan to enter the procurement catalog is 3 or more.
CT Tianqing Pharmaceutical Co., Ltd. has 5 products to be included in the new drug introduction procurement catalog, including the bronchodilator tiotropium bromide inhalation powder aerosol, the schizophrenia treatment drug lurasidone hydrochloride tablets, the bronchospasm reliever drug chloride for inhalation, the systemic antibacterial linezolid tablets, and the hypoglycemic drug sitagliptin phosphate tablets.
Among them, in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions), the sales scale of sitagliptin phosphate tablets in 2022 will be close to 2 billion yuan, a year-on-year increase of 5.57%, and the sales of chlorethiccholine for inhalation in 2023H1 will exceed 10 million yuan, accounting for more than 90% of the total in Chia Tai Tianqing Pharmaceutical City.
2023H1 Brand pattern of chlorethethoxine for terminal inhalation in China's public medical institutions
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Beite Pharmaceutical has 4 products to be added to the new drug procurement catalog, namely postoperative analgesic ketorolac tromethamine injection, gastric acid inhibitor injection famotidine, hemostatic drug aminocaproic acid tablets and heart failure treatment drug digoxin tablets. At the end of China's public medical institutions, the sales of ketorolac tromethamine injection in 2022 exceeded 2.5 billion yuan, a year-on-year increase of 30.17%, and Beite Pharmaceutical and Shandong New Era Pharmaceutical led the market with a share of about 50% and 30% respectively.
Sales trend of terminal ketorolac tromethamine injection in China's public medical institutions in recent years (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Hengrui Pharmaceutical has 3 products to be included in the new drug introduction procurement catalog, including 2 Class 1 new drugs - PARP inhibitor fluzoparib capsule for anti-tumor and remimazolam tosylate for anesthesia sedative injection, and 1 Class 3 generic drug - strong antiemetic drug ondansetron oral dissolving film. According to the data of Minenet, at the beginning of 2022, Hengrui Pharmaceutical's Ondansetron oral dissolving film was approved for marketing, winning the first generic + the first evaluation in China, and Jiangsu Hechen Pharmaceutical and Kelun Pharmaceutical submitted marketing applications for this product in August 2023 and October 2023 respectively, and they are currently in the review and approval stage.
Ondansetron oral dissolving film enterprises apply for listing
Source: Minenet China Declaration Progress (MED) database
In addition, Chongqing Huabang Pharmaceutical, Jiangsu Deyuan Pharmaceutical, Merck & Co., Ltd. and other companies have 3 products in the proposed procurement catalog, covering multiple treatment categories such as dermatological drugs, cardiovascular and cerebrovascular system drugs, digestive system and metabolic drugs, and systemic anti-infective drugs, so as to further meet the clinical drug needs of different patients.
It is proposed to introduce a new drug procurement catalog
Note: Band * is an exclusive variety
Source: Minenet database, official website of West China Second Hospital of Sichuan University
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics, and the above sales are calculated based on the average retail price of products at the terminal. The statistics are as of January 4, 2024, if there is any omission, please correct!